Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.
On the one hand, only 29 drug developers launched IPOs in the US during the first half of this year,...





